Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celldex Differentiated Immuno-Oncology Asset Ripe For Combos

This article was originally published in The Pink Sheet Daily

Executive Summary

Celldex Therapeutics will initiate Phase I/II trials of its immunotherapy varlilumab in combination with Bristol’s PD-1 inhibitor nivolumab this year and is exploring multiple other combinations.

Advertisement

Related Content

Faster FDA Review A Possibility For Celldex’s Rintega After Phase II
Earnings Updates, In Brief: Alkermes, Celldex, Jazz, United Therapeutics, Bayer
Immunotherapy: Big Pharma’s Seductive Embrace
Oncothyreon Has Big Plans For Alpine Acquisition
Bristol Looking For Deals, Immuno-Oncology And Otherwise
Celldex To Fly Solo With Phase III Trial Of Brain Cancer Vaccine

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS077521

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel